Lipoxin Receptor Agonist BML-111 Alleviates Adjuvant Arthritis in Rats

张力,万敬员,叶笃筠,邓华瑜,汪维伟,沈宜,王亚平
DOI: https://doi.org/10.3321/j.issn:1001-1978.2009.03.008
2009-01-01
Abstract:Aim To investigate the influence of lipoxin receptor agonist BML-111 on the histological changes and the production of pro-inflammatory cytokines in rats with adjuvant arthritis(AA).Methods AA was induced by intradermal injection of complete freund's adjuvant(CFA)into the left hind footpad of SD rats.The rats were then supplemented with BML-111 daily for 3 weeks.The swelling degree of hind paw was recorded and the clinical disease activity of AA was scored.At the end of the experiment,joint tissues were fixed and stained with HE routinely for morphologic evaluation,while the serum was collected for measuring the concentrations of TNF-α and IL-6 by ELISA.Results The swelling degree of hind paw and the clinical disease activity of AA was significantly decreased in BML-111-treated AA rats.Treatment of BML-111 attenuated the histopathological lesions of the joints.The concentrations of serum TNF-α and IL-6 were also decreased after BML-111 administration.Conclusions Lipoxin receptor agonist BML-111 alleviates CFA-induced adjuvant arthritis in rats.Lipoxin can also regulate chronic immune-mediated inflammatory process,implicating the potential pharmacological value of lipoxin in the clinical management of patients with chronic inflammatory diseases such as RA.
What problem does this paper attempt to address?